NDA 019908/S-040, S-044, S-047
NDA 021774/S-021, S-025, S-028

SUPPLEMENT APPROVAL

Sanofi-aventis U.S. LLC
Attention: Sudhakarr Balasubramanian
Manager, Regulatory Affairs
55 Corporate Drive
Bridgewater, NJ 08807

Dear Mr. Balasubramanian:

Please refer to your supplemental new drug applications (sNDAs) dated and received January 13, 2017 (S-040 and S-021), March 9, 2018 (S-044 and S-025), and October 13, 2020 (S-047 and S-028), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ambien (zolpidem tartrate) tablets (NDA 019908) and Ambien CR (zolpidem tartrate) extended-release tablets (NDA 021774).

We acknowledge receipt of your amendments dated November 5, 2019 and June 18, 2021, which constituted a complete response to our July 11, 2017 and June 22, 2020 action letters (NDA 019908/S-040 and NDA 021774/S-021).

We acknowledge receipt of your amendments dated December 6, 2019 and April 5, 2021, which constituted a completed response to our December 7, 2018 and April 6, 2020 action letters (NDA 019908/S-044 and NDA 021774/S-025).

These Prior Approval supplemental new drug applications provide for the addition of information related to abuse and dependence, delirium, and the concomitant use of opioids to the Medication Guide and the following sections of the Prescribing Information for Ambien and Ambien CR:

- Highlights of Prescribing Information
- Dosage and Administration (Section 2.1)
- Warnings and Precautions
    - Section 5.5 Abnormal Thinking and Behavioral Changes
    - Section 5.7 Respiratory Depression
- Adverse Reactions (Section 6.2)
- Drug Interactions (Section 7.1)
- Drug Abuse and Dependence (Section 9.3)
- Patient Counseling Information (Section 17)

APPROVAL & LABELING

We have completed our review of these applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email Ann Sohn, Regulatory Project Manager, at ann.sohn@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tiffany R. Farchione, MD
Director
Division of Psychiatry
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TIFFANY R FARCHIONE
02/23/2022 04:03:44 PM